A GGGGCC-repeat expansion in C9orf72 is the most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) among Caucasians. However, little is known about the variability of the GGGGCC expansion in different tissues and whether this correlates with the observed phenotype. Here, we used Southern blotting to estimate the size of hexanucleotide expansions in C9orf72 in neural and non-neural tissues from 18 autopsied ALS and FTD patients with repeat expansion in blood. Digitalization of the Southern blot images allowed comparison of repeat number, smear distribution and expansion band intensity between tissues and between patients. We found marked intra-individual variation of repeat number between tissues, whereas there was less variation within each tissue group. In two patients, the size variation between tissues was extreme, with repeat numbers below 100 in all studied non-neural tissues, whereas expansions in neural tissues were 20-40 times greater and in the same size range observed in neural tissues of the other 16 patients. The expansion pattern in different tissues could not distinguish between diagnostic groups and no correlation was found between expansion size in frontal lobe and occurrence of cognitive impairment. In ALS patients, a less number of repeats in the cerebellum and parietal lobe correlated with earlier age of onset and a larger number of repeats in the parietal lobe correlated with a more rapid progression. In 43 other individuals without repeat expansion in blood, we find that repeat sizes up to 15 are stable, as no size variation between blood, brain and spinal cord was found.
Introduction
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) (OMIM105550) are fatal neurodegenerative diseases with clinical, pathological and genetic overlaps. Mutations in several genes have been implicated in either one, e.g. MAPT in FTD and SOD1 in ALS, or in both diseases, e.g. TARDBP, VCP and FUS (1). The genetic link was further established in 2011 when a mutation in the gene Chromosome 9 open reading frame 72 (C9orf72) (GenBank reference NM_001256054.1, OMIM614260) was found to be the most common cause of both ALS and FTD among Caucasians (2, 3) . The function of the C9orf72 protein is unclear but recent studies suggest it to be involved in the regulation of membrane trafficking in protein degradation processes (4) (5) (6) . The C9orf72 mutation consists of an expanded GGGGCCrepeat sequence located in the intron between the non-coding exons 1a and 1b. In peripheral blood leucocytes, two repeats is the most common size reported in healthy control populations. Sizes above [25] [26] [27] [28] [29] [30] repeats are generally classified as pathological, with most patients having more than 1000 repeats. The lower limit of repeats required for pathogenesis has not been determined (7) . How the expansion mutation causes neurodegeneration is unknown. The prevailing hypotheses include haploinsufficiency with loss of function of the C9orf72 protein (2, 8, 9) , toxicity caused by the formation of sense/anti-sense RNA foci (2, 10, 11) or by aggregation of repeat-associated non-ATG translated poly-dipeptide proteins (12) (13) (14) . It is presently unclear if and how the size of the repeat expansion affects these mechanisms and thereby, phenotypic outcome. The hexanucleotide-repeat region has primarily been studied using repeat-primed polymerase chain reaction (RP-PCR), sometimes in combination with amplicon-length analysis and more rarely Southern blotting. For accurate size estimation of both normal and expanded alleles, a combination of all three methods is recommended (15) . In a few studies, attempts have been made to correlate expansion size, mainly measured in blood, and disease phenotype (16) (17) (18) (19) . The results have been diverging, probably due to less patient number and a limited number of tissue specimens studied from each patient. Also, even though Southern blotting is considered to be the 'Gold Standard' for the size estimation of large repeat expansions, the large variability of the GGGGCC-repeat expansions gives rise to indistinctive smeary bands, probably due to the presence of many different clones with slightly different expansion sizes, making measurements of repeat number difficult. We here used Southern blotting to study the variability of the C9orf72-repeat expansion in tissue specimens from 13 ALS/progressive bulbar palsy (PBP) patients, two FTD patients and three patients with both ALS and FTD. Our focus was neural tissues (spinal cord, frontal lobe, parietal lobe and cerebellum) which were compared with the muscle, heart, kidney, skin and spleen. The aims were to determine the somatic heterogeneity of expansion size in different tissues within a patient and between patients with different phenotypes and to study whether expansion size correlates with phenotype. For the analysis of the Southern blot images, we used a novel method where each image was scanned and digitalized. This enabled us to compare differences of the most abundant band in the samples but also to study variations in smear pattern and intensity between the samples.
Results

Differences in the expansion pattern between different tissues but not between disease phenotypes
We initially investigated the C9orf72 hexanucleotide expansion in autopsied tissue samples of neural and non-neural origins from 18 patients with classical ALS (n = 10), PBP (n = 3), FTD (n = 2) or ALS + FTD (n = 3) where a GGGGCC-repeat expansion had been detected in blood. Two expansion-negative individuals were also selected for analysis (referred to as controls 1 and 2). Disease phenotype and characteristics for each of the expansion-positive patients are listed in Table 1 and a list of the material analyzed are listed in Supplementary material, Table S1A and B. All tissues were initially analyzed using RP-PCR and amplicon-length analysis to determine the C9orf72 genotype (Supplementary material, Table S2 ). The results were consistent in all tissues from the same patient. Southern blotting was then used to investigate the size of the C9orf72 hexanucleotide expansion in the different tissues. For statistical analysis, the Southern blot images were digitalized, wild-type (WT) and expansion regions defined, and intensity of samples scaled. Representative Southern blot images of one ALS patient ( patient 7), one FTD patient ( patient 15) and one ALS + FTD patient ( patient 17) are presented in Figure 1A -F (Southern blot images for all patients can be found in Supplementary material, Figs S1-S38). Differences in the number of repeats between tissues were found in all patients (Figs 1 and 2A) . However, in patients 9 and 11, the differences between neural tissues and non-neural tissues (range ∼1600-3500 repeats and 61-92 repeats, respectively) were extreme (Figs 1G and H, small expansion indicated by arrow, 2A and Supplementary material, Figs S16 and S30-S32). Furthermore, the spinal cord samples of these two patients showed a mixed pattern with both large Table S3 ) and multivariate modeling with orthogonal partial least-squares projections to latent structures (OPLS)-discriminant analysis (DA) (20) was used to assess the inter-individual variations of expansion size together with smear distribution and sample intensity (Supplementary material, Table S4 ). We find that blood differed the most from all other tissues and was found to cluster into two distinct groups (Fig. 2B ). However, no clinical characteristics were associated with this grouping. Repeat number, smear distribution and sample intensity in the frontal and parietal lobes were highly similar and comparisons of different regions of the spinal cord showed no significant differences in repeat size or smear distributions ( Fig. 2B and Supplementary material, Table S4 ). The repeat expansions in heart muscle were larger than in skeletal muscles ( Fig. 2B ), but the differences were not significant (Supplementary material, Table S4 ). The skeletal muscles were similar in repeat number, smear distribution and sample intensity, and the expansion sizes were in general smaller than in the non-cerebellar neural tissue samples ( Fig. 2B and Supplementary material, Table S4 ). The exception was the temporal muscle that was found to have large repeat expansions with highly variable repeat numbers between patients and presented a cluster pattern similar to that observed in blood ( Fig. 2B and Supplementary material, Table S4 ). In the skin and spleen, there was large variability of repeat sizes, whereas the variability was smaller in the kidney (Fig. 2B ). Multivariate modeling using OPLS-DA was not able to classify the patients according to diagnosis or site of disease onset based on differences in repeat number, smear distribution or intensity of individual tissues or blood.
Correlations between repeat lengths and disease characteristics
Patients were grouped according to the clinical phenotype, a group of patients with a motor neuron phenotype (ALS, including PBP; n = 13) and a group of patients with overt, clinical frontotemporal involvement (FTD ± ALS, n = 5). Correlations with P-values between expansion size in brain tissues and age of onset, disease duration and age at death are presented in Supplementary material, Table S5 . A correlation between the number of repeats and the age of onset in frontal lobe observed in an earlier study (17) could not be confirmed in our material, neither in the overall cohort (Fig. 3A) nor in the motor neuron disease-only group (Fig. 3B ). However, a correlation was found between the age of onset and expansion size in both the parietal lobe and cerebellum where a larger expansion correlated with older age at disease onset. Interestingly, a significant P-value was observed only for the ALS group and not the overall cohort ( Fig. 3C-F ). In the parietal lobe, a significant correlation was also found between the number of repeats and the disease duration in both the overall cohort ( Fig. 3G ) and in the ALS group (Fig. 3H) , with a larger number of repeats being associated with a shorter disease duration.
No correlation was found between repeat length and the age of death of the patient. The repeat lengths in the spinal cord, muscle, blood, kidney, spleen and skin were not correlated with any of the disease characteristics investigated.
Patients with extreme variation in expansion size between neural and non-neural tissues
To investigate the extreme variation in repeat number found in patients 9 and 11, additional areas of their CNS (temporal lobe, occipital lobe, cerebellar vermis, hippocampus, amygdala, thalamus, mesencephalon and pons) were examined (Supplementary material, Figs S35 and S38). In both patients, these tissues had large expansions similar to the other brain tissues. However, as observed in the spinal cord segments of these two patients, some of the additional specimens showed banding also in the lower expansion range, a phenomenon not observed in a patient with large expansions in both non-neural and neural tissue (patient 18, Supplementary material, Figs S36 and S37). To ensure that the extreme variation observed between neural and nonneural tissues was not caused by sample mix-up or chimerism, individual-based genotype profiling was performed on DNA from blood, muscle, cerebellum, frontal lobe and cervical spinal cord from patients 9 and 11 as well as two other patients ( patients 10 and 15) and expansion-negative controls 1 and 2. The genotype profiles obtained for each tissue were consistent within each individual examined; hence, the possibility of chimerism or sample mix-up could be excluded (Supplementary material, Table S6 ).
Validation of the non-pathogenic hexanucleotide repeat pattern in the neural tissue of patients lacking expansion in blood
Because of the extreme variation in expansion size observed between neural and non-neural tissues in patients 9 and 11, we next analyzed CNS tissue from 43 individuals (control individuals 1 and 2, 34 patients with ALS, 7 patients with other neurodegenerative conditions), with less than 16 repeats in DNA extracted from blood (41 individuals) or muscle (2 individuals). Using RP-PCR and amplicon-length analysis, the repeat number was determined in frontal lobe and cervical and lumbar spinal cord specimens. We found no evidence for the presence of somatic mosaicism as the GGGGCC-repeat numbers were stable between tissues of all 43 individuals (Table 2 ). In controls 1 and 2, additional tissues of both neural and non-neural origin were analyzed (Supplementary material, Table S1A ) and the number of repeats was found to be constant throughout the material.
Discussion
We investigated the size of the C9orf72 hexanucleotide expansion in different tissues of 18 patients with ALS and/or FTD using Southern blotting. Somatic heterogeneity was observed in all 18 patients but no significant differences could be found between diagnostic subgroups regarding repeat number, relative smear distribution or sample intensities. The expansion size variations within each tissue group (inter-individual variation) were generally smaller than the intra-individual variations, suggesting that certain properties of each tissue might influence the size of the expansion. Blood appeared to be different from the other tissues with a bimodal clustering of the measured repeat numbers (Fig. 2B) . Furthermore, of all other tissues studied, only the temporal muscle presented a somewhat similar bimodal pattern. Noticeably, the patients having large expansions in this muscle also had large expansions in blood. The temporal muscle was also markedly different from all other muscles studied, with larger total expansion sizes and more inter-individual variation. A possible explanation is that the jaw closing muscles differ from other skeletal muscles in terms of embryonic origin, structure and molecular composition (21) (22) (23) . In the cerebellum, the size of the expansion was found to be smaller and the smearing of the samples more limited compared with other brain regions and spinal cord, suggesting that the variability of repeat number in this tissue is lower (17) . Similar observations have been made in trinucleotide-repeat expansion disorders, where expansions in the cerebellum have been found to be shorter than in other brain regions (24) . Previous smaller studies have shown varying results when correlating disease characteristics and expansion size (16) (17) (18) (19) . Two studies reported correlations proposing that a smaller expansion size in blood and frontal lobe is associated with an earlier age of disease onset, and a larger repeat size in the cerebellum is correlated with a shorter disease survival (17, 19) . We here observe the same trends with a lower repeat number being correlated with an earlier age of onset (cerebellum and parietal lobe) and large expansions to a more rapid disease progression ( parietal lobe), even though our observations were made in different tissues. No significant correlation between expansion size and disease characteristics was observed in patients with frontal lobe cognitive dysfunction, although they were few in this study. We found no correlation between repeat number in the spinal cord and any disease parameters. However, a caveat of this and other autopsy studies are that the sampling has been performed at end stage when many of the primarily involved cells (motor neurons) have degenerated. Most of the DNA extracted from the spinal cord is likely to reflect the remaining non-neuronal cell populations, in particular astrocytes.
There are few reports of patients with less than 200 repeats in blood and/or other non-neural tissues (16) (17) (18) (19) 25, 26) , and in only two studies, the expansion pattern in both neural and nonneural tissues have been compared (17, 26) . In the present study, we identified two patients with a repeat number below 100 repeats in non-neural tissues, whereas the expansions in CNS were 20-40 times larger. To our knowledge, no other nucleotide repeat disease has shown a variation in this magnitude between neural and non-neural tissues. As we could exclude chimerism, the most likely explanation for this pattern is somatic mosaicism (27) caused by a mutational event occurring early during embryogenesis. Regarding possible effects on the disease outcome, one study suggest that small expansions may not affect gene transcription or mRNA stability in vivo (9) . However, as the small expansions have only been found in non-neural tissues, these might not affect pathogenesis. Further investigation of this rare patient group is needed in order to determine if all patients with small/intermediate expansions in blood have the same pattern with large expansions in all areas of the CNS or if there are areas of the CNS with only small and other areas with only large expansions.
The lower threshold for the number of repeats in the CNS needed for pathogenesis is at present unknown as there have not been any studies of multiple tissue specimens from patients with a normal or intermediate repeat number measured in blood. In the present study, we found no differences between repeat numbers of non-expanded alleles in different tissues. Another study has presented similar findings (28), and our combined results suggest that repeat sizes below 16 are somatically stable. One of our patients with a large C9orf72 hexanucleotide expansion also had a smaller allele with an intermediate repeat number (30 repeats) that also showed stability in all tissues, which could indicate that expansion instability occurs only above this level.
In summary, in this autopsy study of 18 patients with an expanded allele and 43 individuals without expansion, we find that there is extensive intra-individual variation of the expanded allele, but that repeat sizes up to at least 15 are stable. The results suggest a correlation between disease duration and the size of the C9orf72-hexanucleotide repeat expansion in the parietal lobe and between age of onset and expansion size in the parietal lobe and cerebellum: when expanded, a lower repeat number is associated with symptomatic onset at an earlier age, but slower disease progression, and conversely a larger expansion is associated with older age of onset and a shorter survival after onset of symptoms.
Materials and Methods
Patient material and DNA extraction
Blood samples from patients in the autopsy biobank at Umeå University were screened for the C9orf72 GGGGCC-repeat Allele 1  Allele 2  Allele 1  Allele 2  Allele 1  Allele 2  Allele 1  Allele 2   Control 1  2  5  2  5  2  5  2  5  Control 2  2   a   2   a   2  2  --2  2  3  2 expansion as described previously (15) . Autopsy material from 18 patients having an expansion (referred to as patients P1-18) and two without expansion (referred to as control 1 and control 2) were used for the Southern blot experiments. Ten of the patients with C9orf72 expansion had been diagnosed with ALS, 3 with PBP, 2 with FTD and 3 with a combination of ALS and FTD according to the EFNS Consensus Criteria (ALS) or the Manchester Criteria (FTD) (29, 30) . Details of the patients and tissue samples studied are summarized in Table 1 and Supplementary material, Table S1A and B. For the RP-PCR and amplicon-length analysis experiments, autopsy material from 41 additional patients (34 ALS and 7 with other neurological diseases) lacking a C9orf72 expansion in blood were included. The autopsies were performed during the years 1994-2014 and post-mortem times varied between 8 and 90 h. The autopsy material was fresh frozen and stored at −80°C until use. DNA from autopsy material was extracted using the standard procedures. In short, tissues were cut into small pieces and lysed in buffer containing 50 m TrisHCl, pH 8.0, 100 m EDTA, 1% SDS, 100 m NaCl and 300 µg/ml proteinase K at 55°C followed by phenol:chloroform purification and DNA precipitation. Blood samples from the patients with C9orf72-expansion and from 41 of the 43 expansion-negative individuals described above and from 1 expansion-positive and 1 expansion-negative control used in all Southern Blot experiments were collected during 1993-2014 and stored as buffy coats at −80°C until DNA extraction (from two individuals DNA was extracted from the muscle since no blood was available). DNA from blood/muscle was extracted using the NUCLEON BACC2 (GE Healthcare) according to the manufacturer's recommendations.
Ethical approval
The study was approved by the regional ethical review board for medical research. Informed consent was obtained from the relatives, and when possible, also from the patients before they died.
Southern blot, RP-PCR and amplicon-length analysis
Southern blot was performed as previously described (15) . In brief, 10-20 µg DNA was digested with XbaI and HindIII and separated on a 0.8% agarose gel together with a λ/HindIII DNA ladder labeled with α 32 P-dCTP (PerkinElmer). DNA was then transferred to a Hybond XL nitrocellulose membrane (GE healthcare) through the alkaline transfer. After pre-hybridization in buffer containing 0.5  sodium phosphate, 7% SDS, 0.5 m EDTA and 50 µg/ml denatured salmon sperm DNA, hybridization was performed using a 1 kb DNA probe labeled with α 32 P-dCTP (PerkinElmer) and the signal was detected through phosphor imaging on a Typhoon 9400 Variable Mode Imager (Amersham Biosciences). RP-PCR and amplicon-length analyses were performed as previously described using the 3730xl DNA analyzer (Applied Biosystems) and PeakScanner Software v1.0 or v2.0 (Applied Biosystems) (15) . For repeat numbers of the non-expanded alleles, see Supplementary material, Table S2 and Table 2 .
Data processing
Southern blot data were imported in .tif format standardized to 254 dpi into Matlab R2014a (Mathworks). A standardized area (11 pixels, the middle pixel ±5 pixels) was defined in each lane. Position of the most abundant peak was determined for the wild-type area (2.0-3.0 kb), the small expansion area (a dynamic range defined from above the wild-type peak with an upper limit defined to not include artificial bands) and the large expansion area (7.1-24 kb) region. The large expansion region was divided into 10 regions each integrated for the peak area (to describe the position and distribution of smears within lanes). Each area was normalized to the number of pixels. Intensity within the lanes were scaled from 0 (=white) to 1 (=black) and the distribution of intensities were calculate to reflect the contrast within the lane. The ladder (0.6, 2.0, 2.3, 4.4, 6.6, 9.4 and 23.1 kb) was used to convert the position in gel to size of fragment. Since we could not obtain an exponential function that was linear over the whole gel, we only used ladder sizes 2.0-4.4 kb for size conversion of the wild-type and small expansion fragments and ladder sizes 6.6-23.1 kb for the size conversion of the large expansion fragments. The number of repeats of the expanded alleles was largely as has been described previously (25) . In short, the size of the corresponding fragment was subtracted by the fragment size without the repeated region and then divided by 6 (one repeat unit).
Data analysis
An expansion positive control was used as a quality standard and for the visualization of the repeatability between gels. The analytical variability was inspected by plotting the position of the wild-type allele toward the position of the large expansion size for the positive control (Supplementary material, Fig. S39 ).
Wilcoxon signed-rank tests were used to test for differences of repeat expansion size in the different tissues and blood. No corrections for multiple testing were made due to the exploratory nature of the study. Before performing multivariate analysis, the data were centered and scaled to unit variance. Position, smear and intensity were overviewed in all samples using principal component analysis (PCA) (31) . PCA is used for the visualization of variation in multiple variables and may detect groups, trends and outliers. The same comparisons (as with the Wilcoxon signed-rank test) were made using OPLS-DA (20) to allow differences in smear differences and intensity between samples to be investigated. Pearson's correlation was calculated for repeat expansion size toward age at onset, disease duration and age at death. Multivariate correlation between repeat expansion size, smear differences and intensity toward age at onset, disease duration and age at death were modeled using OPLS (32) . Classification using OPLS-DA of ALS, PBP, ALS + PBP, FTD and ALS + FTD and site of onset were made from the combined signature of repeat expansions and intensity differences in the large expansion region. A combined signature based on all tissues and blood (repeat expansion as the variable for each tissue) was further modeled for the same classifications.
Genotype profiling 1 ng of genomic DNA from each tissue sample was used for the amplification of 10 short tandem-repeat loci using the AuthentiFiler ™ PCR Amplification Kit (Applied Biosystems) according to the manufacturer's instructions. Fragment lengths were detected in a 3730xl DNA analyzer (Applied Biosystems) and analyzed using PeakScanner Software v1.0 or v2.0 (Applied Biosystems).
